Hopefully the acquisition of Global Blood Therapeutics will go better than Pfizer’s last foray into sickle cell deal-making.
Novel approaches including gene editing are creeping towards approval.
How can the company wring the most value from Pyrukynd?
Will upping the dose and changing the primary endpoint pay off?
February will also see an outcome for Gilead's long-acting HIV therapy, and a key FDA panel for me-too checkpoint MAbs.